Abstract | BACKGROUND: METHODS/DESIGN:
Telmisartan in the management of abdominal aortic aneurysm (TEDY) is a multicentre, parallel-design, randomised, double-blind, placebo-controlled trial with an intention-to-treat analysis. We aim to randomly assign 300 participants with small abdominal aortic aneurysm to either 40 mg of telmisartan or identical placebo and follow patients over 2 years. The primary endpoint will be abdominal aortic aneurysm growth as measured by 1) maximum infra-renal aortic volume on computed tomographic angiography, 2) maximum orthogonal diameter on computed tomographic angiography, and 3) maximum diameter on ultrasound. Secondary endpoints include change in resting brachial blood pressure, abdominal aortic aneurysm biomarker profile and health-related quality of life. TEDY is an international collaboration conducted from major vascular centres in Australia, the United States and the Netherlands. DISCUSSION: TRIAL REGISTRATION: Australian and Leiden study centres: Australian New Zealand Clinical Trials Registry ACTRN12611000931976 , registered on 30 August 2011; Stanford study centre: clinicaltrials.gov NCT01683084 , registered on 5 September 2012.
|
Authors | Dylan R Morris, Margaret A Cunningham, Anna A Ahimastos, Bronwyn A Kingwell, Elise Pappas, Michael Bourke, Christopher M Reid, Theo Stijnen, Ronald L Dalman, Oliver O Aalami, Jan H Lindeman, Paul E Norman, Philip J Walker, Robert Fitridge, Bernie Bourke, Anthony E Dear, Jenna Pinchbeck, Rene Jaeggi, Jonathan Golledge |
Journal | Trials
(Trials)
Vol. 16
Pg. 274
(Jun 17 2015)
ISSN: 1745-6215 [Electronic] England |
PMID | 26081587
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Angiotensin II Type 1 Receptor Blockers
- Benzimidazoles
- Benzoates
- Biomarkers
- Telmisartan
|
Topics |
- Angiotensin II Type 1 Receptor Blockers
(adverse effects, therapeutic use)
- Aortic Aneurysm, Abdominal
(blood, diagnosis, drug therapy, physiopathology, psychology)
- Aortography
(methods)
- Benzimidazoles
(adverse effects, therapeutic use)
- Benzoates
(adverse effects, therapeutic use)
- Biomarkers
(blood)
- Blood Pressure
(drug effects)
- Clinical Protocols
- Disease Progression
- Double-Blind Method
- Humans
- Intention to Treat Analysis
- Quality of Life
- Queensland
- Research Design
- Telmisartan
- Time Factors
- Tomography, X-Ray Computed
- Treatment Outcome
|